TRAVERE THERAPEUTICS, INC.: 10-Q filed 2012-10-10

Name: TRAVERE THERAPEUTICS, INC.: 10-Q filed 2012-10-10
Creator: TRAVERE THERAPEUTICS, INC.

What TRAVERE THERAPEUTICS, INC. reported in its quarterly report filed 2012-10-10 (fiscal Q2 2012): 11 published measures, 30 facts as tagged in accession 0001225279-12-000219.

This filing

Form: 10-Q (quarterly report)
Filed: 2012-10-10
Fiscal period: fiscal Q2 2012
Accession: 0001225279-12-000219 on SEC EDGAR

Values are as tagged in this filing. A later filing can restate them; each measure links to its history page, which shows the latest-filed value per period. All TRAVERE THERAPEUTICS, INC. filings.

Reported measures

Total assets

Resources recognized on the balance sheet. Book assets are not the market value of the business.

Period	Value	Unit	Days
At 2012-08-31	3,900	USD
At 2012-02-29	3,909	USD

Stockholders equity

The reported residual interest after liabilities. It is an accounting amount, not market capitalization.

Period	Value	Unit	Days
At 2012-08-31	-64,089	USD
At 2012-02-29	-63,080	USD

Net income or loss

Reported profit or loss for the period. Check the filing for attribution, exceptional items and discontinued operations before comparing companies.

Period	Value	Unit	Days
2012-06-01 to 2012-08-31	-3,500	USD	92
2012-02-29 to 2012-08-31	-7,009	USD	185
2011-06-01 to 2011-08-31	-3,525	USD	92
2011-03-01 to 2011-08-31	-7,049	USD	184

Operating cash flow

Cash generated or used by operating activities. Working-capital timing can make this differ substantially from reported income.

Period	Value	Unit	Days
2012-02-29 to 2012-08-31	-9	USD	185
2011-03-01 to 2011-08-31	-49	USD	184

Revenue

Revenue under this specific accounting concept. A missing value is not zero; filers can use other revenue concepts.

Period	Unit	Days
2012-06-01 to 2012-08-31	USD	92
2012-02-29 to 2012-08-31	USD	185
2011-06-01 to 2011-08-31	USD	92
2011-03-01 to 2011-08-31	USD	184

Retained earnings or deficit

Accumulated undistributed earnings or deficit at the reporting date. This balance is not cash available for distribution.

Period	Value	Unit	Days
At 2012-08-31	-143,090	USD
At 2012-02-29	-136,081	USD

Current assets

Assets classified as current under the normal operating cycle or one-year boundary. Not all current assets can be converted immediately into cash.

Period	Value	Unit	Days
At 2012-08-31	3,900	USD
At 2012-02-29	3,909	USD

Interest expense

Borrowing costs recognized as interest expense. This is distinct from cash interest paid and may not include every capitalized borrowing cost.

Period	Value	Unit	Days
2012-06-01 to 2012-08-31	500	USD	92
2012-02-29 to 2012-08-31	1,000	USD	185
2011-06-01 to 2011-08-31	500	USD	92
2011-03-01 to 2011-08-31	1,000	USD	184

Current liabilities

Obligations classified as current under the operating-cycle or one-year boundary. The balance includes more than short-term borrowing.

Period	Value	Unit	Days
At 2012-08-31	67,989	USD
At 2012-02-29	66,989	USD

Additional paid-in capital

Capital contributed above par value under this concept. It records historical contributions, not the current value of the equity or cash on hand.

Period	Value	Unit	Days
At 2012-08-31	78,989	USD
At 2012-02-29	72,989	USD

General and administrative expense

General and administrative costs reported under this concept, separate from selling expense. Filers group overhead differently, so compare presentation before comparing companies.

Period	Value	Unit	Days
2012-06-01 to 2012-08-31	3,000	USD	92
2012-02-29 to 2012-08-31	6,009	USD	185
2011-06-01 to 2011-08-31	3,025	USD	92
2011-03-01 to 2011-08-31	6,049	USD	184

Inspect the source

Entity: TRAVERE THERAPEUTICS, INC. / CIK 0001438533
Captured: 2026-09-20T09:03:46.664Z
SEC response SHA-256: b66a9ecfb78fb2c3fc29384fc9ee702340e57ee037364236a402186d866938b6

Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON

Every published concept a filing tagged, with the periods it covered, as reported in that filing at capture time. Forms 10-K, 10-K/A, 10-Q, 10-Q/A, 20-F, 20-F/A, 40-F, 40-F/A. A filing page needs at least 8 published concepts. Later filings can restate these values; the company history pages show the latest-filed value per period.

Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.

Use this in research

A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.

These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.

Research methodology · Execution and cost assumptions · Check backtest overfitting

Build with the open-source tools

Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.

Read the published dataset with Python

import json
from urllib.request import urlopen

with urlopen("https://canlicapital.com/company-data/0001438533.json") as response:
    record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
    print(concept["tag"], next(iter(concept["observations"])))